{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:59Z","timestamp":1794047459523,"version":"4.8.0"},"reference-count":26,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"7","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>The treatment landscape for multiple myeloma has significantly evolved in the last decade. Notwithstanding, a large proportion of patients continue to relapse and novel combinations continue to be needed. In this phase II study, selinexor, a first-in-class inhibitor of exportin-1 was evaluated in combination with standard daratumumab-bortezomib-dexamethasone (DVd), for the treatment of relapsed and refractory multiple myeloma (RRMM). The aim of the trial was to assess the efficacy and safety of the combination of selinexor with DVd (S-DVd). A total of 57 patients were enrolled in the two parts of the study. Part 1 enrolled a heavily pretreated population with at least three prior lines (PL) of therapy and part 2 enrolled an early relapse population with at least one PL of therapy. The primary endpoint was complete response (CR) rate in part 2 and overall response rate (ORR) in part 1. In the latter, 24 patients were treated with a median of three PL. Overall response rate (ORR) was 50% with two CR. Median progression- free survival (PFS) was 7 months. In part 2, 33 patients were enrolled, with a median of one PL. ORR was 82% and CR or better was 33%. Median PFS was 24 months. In lenalidomide-refractory patients, a median PFS of 22.1 months was observed. Thrombocytopenia was the most common hematological adverse event (69%; grade 3-4: 34%) and nausea, the most frequent non-hematological adverse event (38%; grade 3-4: 6%). Sixty-two percent of the patients required dose modifications. In summary, although the primary endpoint of the study was not met, the combination of S-DVd showed encouraging clinical efficacy with a generally manageable safety profile representing a potential option for the treatment of RRMM patients.<\/jats:p>","DOI":"10.3324\/haematol.2023.284089","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T03:26:56Z","timestamp":1707967616000},"page":"2219-2228","source":"Crossref","is-referenced-by-count":11,"title":["Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, nonrandomized, multicenter GEM-SELIBORDARA study"],"prefix":"10.3324","volume":"109","author":[{"given":"Ver\u00f3nica","family":"Gonz\u00e1lez-Calle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Rodr\u00edguez-Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"De Arriba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Reinoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paz","family":"Ribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Pilar","family":"Gonz\u00e1lez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Sonia","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel T.","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maialen","family":"Sirvent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Cedena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Lahuerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas F.","family":"San-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"63469","doi-asserted-by":"crossref","unstructured":"Puertas B, Gonz\u00e1lez-Calle V, Sobejano-Fuertes E. Novel agents as main drivers for continued improvement in survival in multiple myeloma. Cancers (Basel). 2023; 15(5):1558.","DOI":"10.3390\/cancers15051558"},{"key":"63470","doi-asserted-by":"crossref","unstructured":"Vogl DT, Dingli D, Cornell RF. Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Oncol. 2018; 36(9):859-866.","DOI":"10.1200\/JCO.2017.75.5207"},{"key":"63471","doi-asserted-by":"crossref","unstructured":"Syed YY. Selinexor: first global approval. Drugs. 2019; 79(13):1485-1494.","DOI":"10.1007\/s40265-019-01188-9"},{"key":"63472","doi-asserted-by":"crossref","unstructured":"Chen C, Siegel D, Gutierrez M. Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia. Blood. 2018; 131(8):855-863.","DOI":"10.1182\/blood-2017-08-797886"},{"key":"63473","doi-asserted-by":"crossref","unstructured":"Chari A, Vogl DT, Gavriatopoulou M. Oral selinexor dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019; 381(8):727-738.","DOI":"10.1056\/NEJMoa1903455"},{"key":"63474","doi-asserted-by":"crossref","unstructured":"Grosicki S, Simonova M, Spicka I. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-perweek bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020; 396(10262):1563-1573.","DOI":"10.1016\/S0140-6736(20)32292-3"},{"key":"63475","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Moreau P, Terpos E. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(3):309-322.","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"63476","unstructured":"Moreau P, Kumar SK, San Miguel J. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021; 22(3):e105-e118."},{"key":"63477","doi-asserted-by":"crossref","unstructured":"Mateos M V, Dimopoulos MA, Cavo M. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018; 378(6):518-528.","DOI":"10.1056\/NEJMoa1714678"},{"key":"63478","doi-asserted-by":"crossref","unstructured":"Voorhees PM, Sborov DW, Laubach J. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023; 10(10):e825-e837.","DOI":"10.1016\/S2352-3026(23)00217-X"},{"key":"63479","doi-asserted-by":"crossref","unstructured":"Sonneveld P, Chanan-Khan A, Weisel K. Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial. J Clin Oncol. 2023; 41(8):1600-1609.","DOI":"10.1200\/JCO.21.02734"},{"key":"63480","doi-asserted-by":"crossref","unstructured":"Rajkumar S V, Dimopoulos MA, Palumbo A. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):e538-548.","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"63481","unstructured":"Kumar S, Paiva B, Anderson KC. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-e346."},{"key":"63482","unstructured":"Usmani SZ, Nahi H, Weiss BM. Safety and efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed and refractory multiple myeloma: final results from GEN501 and Sirius. Blood. 2017; 130(Suppl 1):3107."},{"key":"63483","doi-asserted-by":"crossref","unstructured":"Grosicki S, Simonova M, Spicka I. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020; 396(10262):1563-1573.","DOI":"10.1016\/S0140-6736(20)32292-3"},{"key":"63484","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Nahi H, Plesner T. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol. 2020; 7(6):e447-e455.","DOI":"10.1016\/S2352-3026(20)30081-8"},{"key":"63485","doi-asserted-by":"crossref","unstructured":"Lonial S, Weiss BM, Usmani SZ. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. The Lancet. 2016; 387(10027):1551-1560.","DOI":"10.1016\/S0140-6736(15)01120-4"},{"key":"63486","doi-asserted-by":"crossref","unstructured":"Palumbo A, Chanan-Khan A, Weisel K. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016; 375(8):754-766.","DOI":"10.1056\/NEJMoa1606038"},{"key":"63487","doi-asserted-by":"crossref","unstructured":"Spencer A, Lentzsch S, Weisel K. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018; 103(12):2079-2087.","DOI":"10.3324\/haematol.2018.194118"},{"key":"63488","doi-asserted-by":"crossref","unstructured":"Weisel KC, Sonneveld P, Mateos M-V. Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) versus bortezomib and dexamethasone (Vd) in first relapse patients (pts) with multiple myeloma (MM): four-year update of Castor. Blood. 2019; 134(Suppl 1):3192.","DOI":"10.1182\/blood-2019-123527"},{"key":"63489","doi-asserted-by":"crossref","unstructured":"Mateos M-V, Sonneveld P, Hungria V. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR. Clin Lymphoma Myeloma Leuk. 2020; 20(8):509-518.","DOI":"10.1016\/j.clml.2019.09.623"},{"key":"63490","doi-asserted-by":"crossref","unstructured":"Dimopoulos M, Quach H, Mateos M-V. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020; 396(10245):186-197.","DOI":"10.1016\/S0140-6736(20)30734-0"},{"key":"63491","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Quach H, Mateos M-V. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2022; 23(1):65-76.","DOI":"10.1016\/S1470-2045(21)00579-9"},{"key":"63492","doi-asserted-by":"crossref","unstructured":"Moreau P, Dimopoulos M-A, Mikhael J. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021; 397(10292):2361-2371.","DOI":"10.1016\/S0140-6736(21)00592-4"},{"key":"63493","doi-asserted-by":"crossref","unstructured":"Martin T, Dimopoulos M-A, Mikhael J. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. Blood Cancer J. 2023; 13(1):72.","DOI":"10.1038\/s41408-023-00797-8"},{"key":"63494","doi-asserted-by":"crossref","unstructured":"Mikhael J, Noonan KR, Faiman B. Consensus recommendations for the clinical management of patients with multiple myeloma treated with selinexor. Clin Lymphoma Myeloma Leuk. 2020; 20(6):351-357.","DOI":"10.1016\/j.clml.2019.12.026"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284089\/76609","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284089\/77193","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11445\/76609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:44Z","timestamp":1794045944000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":26,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284089","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,15]]}}}